Mid-Atlantic Venture Association BioConnection 2005 To Feature 15 Of The Region's Most Fundable Healthcare Companies

TIMONIUM, Md., May 2 /PRNewswire/ -- Fifteen companies from the industries of biotechnology, medical devices and healthcare services will present to several hundred attendees including venture capitalists, private equity professionals and key professional services providers at the Mid-Atlantic Venture Association's (MAVA) BioConnection 2005 venture fair, May 31st at the Baltimore Marriott Waterfront Hotel in Baltimore, MD. The Co-Chairmen of this year's event are Jim Barrett, General Partner of New Enterprise Associates, and Mark Pacala, Managing Director of Essex Woodland Health Ventures.

"Our goal was to select some of the most fundable healthcare investment opportunities in the market and we are proud that the rigorous BioConnection selection process has identified these 15 high quality presenting companies for our 2005 fair," said Julia Spicer, Executive Director of MAVA. "With the leadership of Jim Barrett and Mark Pacala, coupled with the dozens of venture firms that are working to produce this event, we have a dynamic program for BioConnection 2005."

BioConnection 2005 has received stellar support from the private equity community. Participation by venture funds, whether it be in an advisory, supportive or selection committee role, include The Aurora Funds, The Carlyle Group, Essex Woodland Health Ventures, Grotech Capital Group, Harbert Venture Partners, Intersouth Partners, Lazard Technology Partners, NeuroVentures Capital, New Enterprise Associates, Quaker BioVentures and Toucan Capital.

Companies chosen to fill the 15 coveted BioConnection 2005 presentation slots beat out a pool of highly qualified applicants. MAVA's annual venture fairs have helped shape the region's entrepreneurial economy, generating more than $2.4 billion of venture investments for the participating companies. Some of the region's biggest success stories have presented at one of the association's annual fairs.

Selected companies for BioConnection 2005 include: Company Name Company Name 1. Adlyfe, Inc. 9. Mardil, Inc. 2. Alba Therapeutics Corporation 10. MaxCyte, Inc. 3. Argos Therapeutics, Inc. 11. Protez Pharmaceuticals 4. FemmePharma Global Healthcare, Inc. 12. Rivanna Pharmaceuticals, Inc. 5. GlycoMimetics, Inc. 13. Ruxton Pharmaceuticals, Inc. 6. Innovative Biosensors, Inc. 14. StemCo Biomedical, Inc. 7. Intronn, Inc. 15. Trophogen, Inc. 8. K2M, LLC About MAVA

MAVA facilitates access to deal flow, institutional capital, and resources to support fund operations by offering numerous programming and networking opportunities. Founded in 1986, MAVA represents the collective interests of venture capitalists investing in the mid-Atlantic. Membership includes 500+ venture capital professionals at 125 firms with more than $10 billion in capital under management. Numerous investors participate in MAVA's Life Sciences Investor Roundtable, a group of private equity and venture investors focused on biotech and life sciences investing. In addition, over 250 key professional service providers from the legal, financial, executive search and consulting fields are also MAVA members. For more information, please visit http://www.mava.org/

Mid-Atlantic Venture Association

CONTACT: Stacey Sweeney of the Mid-Atlantic Venture Association,+1-703-281-2254 or +1-571-228-2249, Stacey@StaceySweeney.com

Back to news